Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

Open access

Published version of a preprint

Abstract

UNLABELLED: Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K-AKT activation, prolonged early G1 arrest induced by PD 0332991 (palbociclib) inhibition of CDK4 sensitized resistant lymphoma cells to ibrutinib killing when BTK was unmutated, and to PI3K inhibitors independent of C481S mutation. These data identify a genomic basis for acquired ibrutinib resistance in MCL and suggest a strategy to override both primary and acquired ibrutinib resistance. SIGNIFICANCE: We have discovered the first relapse-specific BTK mutation in patients with MCL with acquired resistance, but not primary resistance, to ibrutinib, and demonstrated a rationale for targeting the proliferative resistant MCL cells by inhibiting CDK4 and the cell cycle in combination with ibrutinib in the presence of BTK(WT) or a PI3K inhibitor independent of BTK mutation. As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. Cancer Discov; 4(9); 1022-35. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 973.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0098

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 275

Metadata

Authors
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., Johnson, A., Chang, B., Ely, S., Elemento, O., Mason, C. E., Leonard, J. P., & Chen-Kiang, S.
Affiliations
  • Weill Cornell Medicine (US)
  • 1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
  • Willamette Valley Cancer Institute and Research Center (US)
  • Cornell University (US)
  • Foundation Medicine (United States) (US)
  • The Ohio State University (US)
  • Pharmacyclics (United States) (US)
Venue
Cancer Discovery
Published
2014-09-01
Volume
4
Issue
9
Pages
1022-1035
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2028681024
Cited by
273
References
39
Citations by year
2026: 4 · 2025: 11 · 2024: 18 · 2023: 13 · 2022: 13 · 2021: 27 · 2020: 32 · 2019: 31 · 2018: 33 · 2017: 30 · 2016: 38 · 2015: 23
FWCI
22.56
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
Funders
  • National Institutes of Health (5t32gm083937-09)
  • Weill Cornell Medical College
  • National Cancer Institute (R21CA176362)
  • National Institute of General Medical Sciences (T32-GM083937)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
mantle cell lymphoma, ibrutinib resistance, BTK C481S mutation, acquired drug resistance, PI3K inhibition, CDK4 inhibition, palbociclib, PIK3IP1, cell cycle reprogramming, G1 cell cycle arrest, combination therapy, Akt activation, relapse
MeSH terms
Agammaglobulinaemia Tyrosine Kinase, Phosphoinositide-3 Kinase Inhibitors, Adenine, Antineoplastic Agents, Cell Cycle, DNA Mutational Analysis, Drug Synergism, Enzyme Activation, Humans, Mutation, Neoplasm Recurrence, Local, Nitrates, Piperidines, Polyethylene Glycols, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Signal Transduction, NF-kappa B, Treatment Outcome, Drug Resistance, Neoplasm, Amino Acid Substitution, Lymphoma, Mantle-Cell, Genomics, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins c-bcr

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0098
The paper
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., Johnson, A., Chang, B., Ely, S., Elemento, O., Mason, C. E., Leonard, J. P., & Chen-Kiang, S. (2014). Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.